|

Pemetrexed (Alimta) Clinical Trials

5 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 3

Top Sponsors

  • Guangzhou Medical University3
  • Intergroupe Francophone de Cancerologie Thoracique1
  • Gustave Roussy, Cancer Campus, Grand Paris1

Indications

  • Cancer5
  • Leptomeningeal Metastasis3
  • Lung Cancer2
  • Intrathecal Drug Delivery1
  • MET Exon 14 Mutation1

Other5 trials

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
Phase 2
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.